Continued research on EZH2 inhibition as a treatment for MCC is warranted to understand the mechanistic role of EZH2 in the activity of MCPyV-positive MCC; however, the incomplete elimination of tumor growth in vivo points to the need to study EZH2 inhibition in combination with other therapies to promote synergy and cell death [26]. This evidence concerns the gene EZH2 and neoplasm.